-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure launches ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer in US

PUBT·07/27/2026 12:33:17
Listen to the news
IceCure launches ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer in US
  • IceCure Medical launched its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer at its first U.S. clinical site.
  • West Cancer Center & Research Institute in Germantown, Tennessee will begin enrolling patients, with Dr. Richard Gilmore leading the site.
  • Study will collect real-world evidence to support broader clinical adoption and expand access following FDA marketing authorization in October 2025.
  • Results have not been presented; data will be generated as enrollment progresses across up to 400 patients at 30 U.S. sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607270832PR_NEWS_USPR_____LN12512) on July 27, 2026, and is solely responsible for the information contained therein.